Tech Company Financing Transactions
Neuromed Pharmaceuticals Funding Round
On 8/21/2007, Neuromed Pharmaceuticals landed $53.3 million in Series E funding from BDC Venture Capital, Growthworks Capital and MPM Capital.
Transaction Overview
Company Name
Announced On
8/21/2007
Transaction Type
Venture Equity
Amount
$53,300,000
Round
Series E
Investors
Proceeds Purpose
"Funding from this round will allow Neuromed to accelerate the development of its promising drugs to treat pain, including NMED-1077 (OROS® Hydromorphone), our recently in-licensed product for chronic pain in Phase 3 clinical development," said Dr. Christopher Gallen, Neuromed's President & CEO.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
Six Tower Bridge 181 Washington Street 440
Conshohocken, PA 19428
USA
Conshohocken, PA 19428
USA
Phone
Website
Email Address
Overview
Neuromed is a privately held biopharmaceutical company developing the next generation of chronic pain drugs with pipeline programs in anxiety, epilepsy and cardiovascular disease such as hypertension.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christopher Gallen
Chief Financial Officer
Bruce Colwill
Chief Scientific Officer
Terrance Snutch
Vice President
Simon Li
Vice President
Gene Wright
VP - Bus. Development
Jeffrey Arcara
VP - Marketing
Mario Orlando
Browse more venture capital transactions:
Prev: 8/21/2007: Telegent venture capital transaction
Next: 8/21/2007: PlaCor venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs